Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Novo Nordisk AS's Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was MXN453,916 Mil. Therefore, Novo Nordisk AS's EV-to-EBIT ratio for today is 8.70.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Novo Nordisk AS's Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was MXN515,926 Mil. Therefore, Novo Nordisk AS's EV-to-EBITDA ratio for today is 7.65.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Novo Nordisk AS's Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was MXN933,500 Mil. Therefore, Novo Nordisk AS's EV-to-Revenue ratio for today is 4.23.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Novo Nordisk AS's Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was MXN90,841 Mil. Therefore, Novo Nordisk AS's EV-to-FCF ratio for today is 43.47.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Novo Nordisk AS (MEX:NOVOBN) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Novo Nordisk AS's current Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN453,916 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Novo Nordisk AS's current Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN515,926 Mil.
Novo Nordisk AS's current Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN933,500 Mil.
Novo Nordisk AS's current Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN340,015 Mil.
Novo Nordisk AS's current Enterprise Value is MXN3,948,897 Mil.
Novo Nordisk AS's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN90,841 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Nordisk AS Enterprise Value Related Terms
Novo Nordisk AS Enterprise Value Historical Data
* Premium members only.
The historical data trend for Novo Nordisk AS's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NOVOBN vs LLY, JNJ, ABBV: Enterprise Value Comparison
For the Drug Manufacturers - General subindustry, Novo Nordisk AS's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novo Nordisk AS Enterprise Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novo Nordisk AS's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Novo Nordisk AS's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Novo Nordisk AS's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Enterprise Value of MXN3,948,897 Mil mean?
Novo Nordisk AS (MEX:NOVOBN) has a Enterprise Value of MXN3,948,897 Mil as of Jun. 24, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Novo Nordisk AS and its competitors.
Is Novo Nordisk AS's Enterprise Value too high?
Novo Nordisk AS's current Enterprise Value is MXN3,948,897 Mil. Overall, Novo Nordisk AS has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Novo Nordisk AS's Enterprise Value compare to LLY and JNJ?
Novo Nordisk AS's Enterprise Value of MXN3,948,897 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Drug Manufacturers company?
A good Enterprise Value depends on the Drug Manufacturers industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Novo Nordisk AS and its competitors. Novo Nordisk AS's current Enterprise Value is MXN3,948,897 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novo Nordisk AS stock overvalued right now?
Based on GuruFocus' analysis, Novo Nordisk AS (MEX:NOVOBN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN2,387.36, compared to a current price of MXN810.00 — trading 66.1% below its estimated fair value. The current Enterprise Value is MXN3,948,897 Mil. Novo Nordisk AS's overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Novo Nordisk AS (MEX:NOVOBN), the current Enterprise Value is MXN3,948,897 Mil as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novo Nordisk AS (MEX:NOVOBN) Overvalued in 2026?
Based on GuruFocus' analysis, Novo Nordisk AS stock appears to be undervalued.
The current stock price of MXN810.00 is trading 66.1% below its estimated GF Value™ of MXN2,387.36.
GuruFocus considers Novo Nordisk AS to be Significantly Undervalued.
Key valuation signals for MEX:NOVOBN:
Enterprise Value: MXN3,948,897 Mil
GF Value™: MXN2,387.36 vs. price of MXN810.00 (66.1% below fair value)
No single metric tells the full story. See the MEX:NOVOBN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
79GF Score
Get the complete analysis for MEX:NOVOBN
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NOVOBN has been successfully added to your 
